Login to Your Account



New Love for SERMs

Ligand Dusts Off Lasofoxifene, Signs 2 Deals for Pfizer Castoff

By Brian Orelli
Contributing Writer

Monday, July 29, 2013

A few years after Ligand Pharmaceuticals Inc. regained the rights to its selective estrogen receptor modulator (SERM) lasofoxifene from Pfizer Inc., the company has dusted off the osteoporosis drug and found new parties interested in moving the molecule forward.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription